Pidilizumab monoclonal antibody therapy following stem cell transplantation
US9580504B1 · kind B1 · utility
7Cited by
16References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 7, 2014 |
| Grant date | Feb 28, 2017 |
| Priority date | — |
| Expiry date | Nov 7, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating specific populations of cancer patients, specifically patients suffering from cancer who undergo stem cell transplantation and were classified as positive by a pre-transplant metabolic imaging, by administering to the subject a therapeutically effective amount of a pidilizumab monoclonal antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.